Is MUSCULAR WEAKNESS a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed MUSCULAR WEAKNESS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 16 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported MUSCULAR WEAKNESS to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and MUSCULAR WEAKNESS. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause MUSCULAR WEAKNESS, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes MUSCULAR WEAKNESS. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if MUSCULAR WEAKNESS ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing MUSCULAR WEAKNESS: 16
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where MUSCULAR WEAKNESS is a reported side effect: 0.4806%

FDA reports of any drug causing MUSCULAR WEAKNESS : 34158
Average percentage for all medicated patients where MUSCULAR WEAKNESS is reported as a complication: 0.2141%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with MUSCULAR WEAKNESS:

TYSABRI (3624 patients)
ASPIRIN (3045 patients)
LIPITOR (2968 patients)
FOSAMAX (2590 patients)
AVONEX (2306 patients)
FORTEO (1933 patients)
CRESTOR (1492 patients)
SIMVASTATIN (1361 patients)
LYRICA (1357 patients)
PREDNISONE (1340 patients)
ZOCOR (1209 patients)
LISINOPRIL (1208 patients)
SYNTHROID (1165 patients)
NEURONTIN (1109 patients)
MAGNEVIST (1107 patients)
HUMIRA (1102 patients)
ZOMETA (1072 patients)
NEXIUM (1051 patients)
OMEPRAZOLE (1007 patients)
ATENOLOL (993 patients)
LASIX (989 patients)
ENBREL (980 patients)
BOTOX (942 patients)
PLAVIX (910 patients)
LEVAQUIN (908 patients)
REBIF (906 patients)
COUMADIN (900 patients)
VITAMIN D (869 patients)
FOLIC ACID (860 patients)
NORVASC (857 patients)
METHOTREXATE (852 patients)
FUROSEMIDE (780 patients)
ACETAMINOPHEN (753 patients)
HYDROCHLOROTHIAZIDE (750 patients)
LEVOTHYROXINE SODIUM (748 patients)
CYMBALTA (744 patients)
OMNISCAN (739 patients)
AREDIA (732 patients)
PROTONIX (721 patients)
AMBIEN (711 patients)
GABAPENTIN (707 patients)
PRILOSEC (678 patients)
SEROQUEL (654 patients)
XANAX (651 patients)
REMICADE (627 patients)
CELEBREX (626 patients)
IBUPROFEN (626 patients)
DEXAMETHASONE (624 patients)
BETASERON (609 patients)
ALBUTEROL (609 patients)
TOPROL-XL (608 patients)
BACLOFEN (607 patients)
VICODIN (603 patients)
CALCIUM (592 patients)
PERCOCET (590 patients)
ALLOPURINOL (587 patients)
LEXAPRO (574 patients)
VIOXX (559 patients)
PREDNISOLONE (559 patients)
ZOLOFT (553 patients)
ZETIA (550 patients)
ATIVAN (544 patients)
PREVACID (543 patients)
PREDNISONE TAB (524 patients)
METFORMIN HCL (523 patients)
POTASSIUM CHLORIDE (517 patients)
LANTUS (513 patients)
DIOVAN (504 patients)
PAXIL (503 patients)
DIGOXIN (499 patients)
DECADRON (496 patients)
WARFARIN SODIUM (490 patients)
METOPROLOL TARTRATE (487 patients)
CLONAZEPAM (481 patients)
AMLODIPINE (480 patients)
EPOGEN (470 patients)
OXYCONTIN (450 patients)
AVELOX (439 patients)
MULTI-VITAMINS (437 patients)
RENAGEL (430 patients)
EFFEXOR (425 patients)
COREG (419 patients)
ACTONEL (409 patients)
NIASPAN (403 patients)
LORAZEPAM (401 patients)
ZOFRAN (397 patients)
OXYCODONE HCL (396 patients)
HEPARIN SODIUM INJECTION (394 patients)
OPTIMARK (386 patients)
KLONOPIN (380 patients)
ADVAIR DISKUS 100/50 (376 patients)
DURAGESIC-100 (376 patients)
CIPROFLOXACIN (373 patients)
CELEXA (370 patients)
INSULIN (367 patients)
MULTI-VITAMIN (363 patients)
CALCIUM CARBONATE (358 patients)
GILENYA (357 patients)
ALPRAZOLAM (353 patients)
TRAMADOL HCL (353 patients)
MORPHINE (347 patients)
FENTANYL (346 patients)
AMOXICILLIN (343 patients)
VITAMIN B-12 (342 patients)
SINGULAIR (340 patients)
METOPROLOL (338 patients)
ALENDRONATE SODIUM (338 patients)
RAMIPRIL (336 patients)
VYTORIN (331 patients)
PROZAC (327 patients)
FLEXERIL (326 patients)
ARANESP (323 patients)
SPIRIVA (319 patients)
ZYRTEC (314 patients)
PREMARIN (312 patients)
VELCADE (308 patients)
VALIUM (308 patients)
CHANTIX (305 patients)
MULTIHANCE (303 patients)
DIAZEPAM (302 patients)
GLUCOPHAGE (302 patients)
FLOMAX (301 patients)
ASCORBIC ACID (301 patients)
FISH OIL (299 patients)
PROHANCE (299 patients)
TRAZODONE HCL (297 patients)
LOVENOX (296 patients)
ZANTAC (292 patients)
NAPROXEN (291 patients)
HUMALOG (290 patients)
ARIMIDEX (289 patients)
MIRALAX (284 patients)
FOSAMAX PLUS D (284 patients)
VALTREX (284 patients)
LORTAB (283 patients)
COZAAR (282 patients)
ACCUTANE (280 patients)
WELLBUTRIN (279 patients)
ELAVIL (278 patients)
AVANDIA (278 patients)
NITROGLYCERIN (277 patients)
CYCLOPHOSPHAMIDE (276 patients)
REVLIMID (275 patients)
VITAMIN E (275 patients)
BONIVA (270 patients)
CLONIDINE (270 patients)
GADOLINIUM IN UNSPECIFIED DRUG (264 patients)
TEGRETOL (262 patients)
METFORMIN (261 patients)
REGLAN (261 patients)
ALLEGRA (258 patients)
CITALOPRAM HYDROBROMIDE (258 patients)
LEVOXYL (258 patients)
LAMICTAL (257 patients)
ENALAPRIL MALEATE (251 patients)
YASMIN (251 patients)
COMPAZINE (250 patients)
ACETYLSALICYLIC ACID SRT (246 patients)
LANSOPRAZOLE (246 patients)
HYDROCODONE (244 patients)
DILAUDID (244 patients)
COLACE (242 patients)
TRICOR (242 patients)
MORPHINE SULFATE (241 patients)
GLEEVEC (239 patients)
FERROUS SULFATE TAB (238 patients)
ACTOS (235 patients)
BOTULINUM TOXIN TYPE A (234 patients)
POTASSIUM (233 patients)
IRON (233 patients)
KEPPRA (232 patients)
ACYCLOVIR (232 patients)
PRAVASTATIN (231 patients)
CYCLOSPORINE (230 patients)
GLIPIZIDE (229 patients)
SPIRONOLACTONE (228 patients)
GLYBURIDE (228 patients)
TAMOXIFEN CITRATE (227 patients)
TYLENOL (227 patients)
PEPCID (225 patients)
HEPARIN (225 patients)
FLUCONAZOLE (225 patients)
MAGNESIUM OXIDE (225 patients)
THALIDOMIDE (224 patients)
FLONASE (224 patients)
PANTOPRAZOLE (224 patients)
FEMARA (222 patients)
CIPRO (221 patients)
FAMOTIDINE (220 patients)
ZITHROMAX (218 patients)
METOPROLOL SUCCINATE (217 patients)
CEPHALEXIN (217 patients)
NYSTATIN (216 patients)
VOLTAREN (216 patients)
EXTAVIA (216 patients)
PROCRIT (215 patients)
LOPRESSOR (213 patients)
ALTACE (213 patients)
ATORVASTATIN CALCIUM (212 patients)
HYDROCODONE BITARTRATE (210 patients)
PROGRAF (209 patients)
AMIODARONE HCL (208 patients)
BOTOX COSMETIC (207 patients)
BENADRYL (207 patients)
TOPAMAX (206 patients)
ZYPREXA (205 patients)
EFFEXOR XR (204 patients)
METRONIDAZOLE (202 patients)
YAZ (202 patients)
METOCLOPRAMIDE (201 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about MUSCULAR WEAKNESS and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.